Freedman Files 13D on Eupraxia Pharmaceuticals

TL;DR

**Freedman ups stake in Eupraxia Pharma - 13D filed!**

AI Summary

Joseph S. Freedman filed a Schedule 13D on October 31, 2024, regarding his beneficial ownership of Eupraxia Pharmaceuticals Inc. common shares. The filing indicates a change in his ownership status, requiring this updated disclosure. Freedman is located at 27 Swansdown Drive, North York, Ontario.

Why It Matters

This filing signals a potential shift in significant beneficial ownership for Eupraxia Pharmaceuticals Inc., which could impact the company's stock and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant changes in ownership by large shareholders, which can lead to increased volatility or strategic shifts for the company.

Key Players & Entities

• Eupraxia Pharmaceuticals Inc. (company) — Subject company
• Joseph S. Freedman (person) — Filing person
• October 31, 2024 (date) — Date of event requiring filing
• 27 Swansdown Drive, North York, Ontario M2L 2N2 (address) — Filing person's address

FAQ

Key Financial Figures

• $5.00 — eries 1 preferred shares at a price of C$5.00 per preferred share (the " Preferred Sh
• $15,839,915 — ") for an aggregate purchase price of C$15,839,915. Prior to entering into the Agreement,
• $4.18 — h were acquired at an average price of C$4.18 per Common Share and warrants exercisab
• $1.36 — h were acquired at an average price of C$1.36 per warrant (the " Warrant Shares ").

Filing Documents

• f80836234.htm (SC 13D) — 39KB
• 0000899140-24-001143.txt ( ) — 40KB

PURPOSE OF TRANSACTION

ITEM 4. PURPOSE OF TRANSACTION The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person acquired the securities reported herein in connection with open market purchases, participation in a non-brokered private placement on August 8, 2023, participation in an overnight marketed offering on March 15, 2024 and participation in a non-brokered private placement on October 31, 2024. The Reporting Person intends to participate in the management of the Issuer through representation on the Issuer's Board of Directors. Except as set forth in this Schedule 13D, the Reporting Person has no plans or proposals at present that relate to or would result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. The Reporting Person intends to regularly review their investment in the Issuer. Based on such review as well as other factors (including, among other things, their evaluation of the Issuer's business, prospects and financial condition, the market price for the Issuer's securities, other opportunities available to them and general market, industry and economic conditions), the Reporting Person, and/or other persons affiliated with them, may, and reserve the right to, evaluate their investments and make strategic decisions based thereon, including disposing of, or causing to be disposed, a portion of the securities beneficially owned by them, in the public market through open market sales, registered or unregistered block trades, in privately negotiated transactions or otherwise. The Reporting Person may formulate such plans or proposals for, and may from time to time explore, or make such proposals relating to, transactions or actions which relate to or would result in any of the matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER The information set forth in or incorporated by reference

View Full Filing

View this SC 13D filing on SEC EDGAR